TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06142084

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein-free meal
Description: Participants will consume a protein-free meal to correct analyses for endogenous protein losses.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein-free meal
Description: Participants will consume a protein-free meal to correct analyses for endogenous protein losses.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein-free meal
Description: Participants will consume a protein-free meal to correct analyses for endogenous protein losses.
Study: NCT06387017

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: stool collection
Description: stool collection
Study: NCT05365854

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alveolar Recruitment Maneuver (ARM)
Description: When patient is under general anesthesia, an arterial catheter is placed for cardiac output and stroke volume (SV) monitoring. To avoid pre-load dependency bias, the blood volume will be optimized. A 250mL fluid-challenge of a balanced crystalloid solution is administered under cover of the SV monitoring. If SV variation is greater than 10%, a new fluid-challenge is performed to obtain a reference SV, corresponding to the patient's optimal blood volume.The patient is then pre-load independent.~Then, patients will be randomized into two groups: a first group will receive a CPAP ARM: 40 cmH2O for 50 seconds, followed by a 10-minute break corresponding to a period of return to basal state; then an extended sigh ARM (e-sigh) also lasting 50seconds (driving pressure: 10cmH2O and successive PEEP levels at 10,15,20,25 and 30cmH2O, a respiratory rate set at 30/min in controlled pressure - 5cycles at each PEEP level); a second group will receive the same two ARM modalities in reverse order.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alveolar Recruitment Maneuver (ARM)
Description: When patient is under general anesthesia, an arterial catheter is placed for cardiac output and stroke volume (SV) monitoring. To avoid pre-load dependency bias, the blood volume will be optimized. A 250mL fluid-challenge of a balanced crystalloid solution is administered under cover of the SV monitoring. If SV variation is greater than 10%, a new fluid-challenge is performed to obtain a reference SV, corresponding to the patient's optimal blood volume.The patient is then pre-load independent.~Then, patients will be randomized into two groups: a first group will receive a CPAP ARM: 40 cmH2O for 50 seconds, followed by a 10-minute break corresponding to a period of return to basal state; then an extended sigh ARM (e-sigh) also lasting 50seconds (driving pressure: 10cmH2O and successive PEEP levels at 10,15,20,25 and 30cmH2O, a respiratory rate set at 30/min in controlled pressure - 5cycles at each PEEP level); a second group will receive the same two ARM modalities in reverse order.
Study: NCT05832554

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nasal airway
Description: nasopharyngeal airway

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: oral airway
Description: oropharyngeal airway
Study: NCT06142084

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein-free meal
Description: Participants will consume a protein-free meal to correct analyses for endogenous protein losses.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein-free meal
Description: Participants will consume a protein-free meal to correct analyses for endogenous protein losses.
Study: NCT04879524

Intervention type: PROCEDURE
Intervention: Percutaneous infracoccygeal Botulinum toxin injection to puborectalis
Description: The intervention is an injection of 200 units of Botulinum toxin type A in to the puborectalis muscle under ultrasound guidance.~In the prone position, the puborectalis muscle will be identified below the coccyx using ultrasound. After skin preparation using 70% Isopropyl Alcohol Pad, and up to 5ml of local anaesthetic (1% lidocaine), an electromyography (EMG) needle will be inserted and the puborectalis muscle stimulated using a current to confirm correct needle position. 200 units of BTXA (Botox, Allergan, Ireland) prepared in 2 ml of saline solution and drawn up using a 2ml syringe. 1ml (100 units) of BTXA solution is injected through the EMG needle into the puborectalis muscle to each side of the midline, achieving a total of 200 units. The needle is withdrawn, and the procedure is complete.
Study: NCT04122456

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultraviolet B Radiation
Description: One skin punch biopsy will be taken to the laboratory for exposure to ultraviolet B radiation. After 1-hour incubation, the biopsies will be bisected in half.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultraviolet B Radiation
Description: One skin punch biopsy will be taken to the laboratory for exposure to ultraviolet B radiation. After 1-hour incubation, the biopsies will be bisected in half.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Ultraviolet B Radiation
Description: One skin punch biopsy will be taken to the laboratory and will be kept as a non-irradiated control.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Ultraviolet B Radiation
Description: One skin punch biopsy will be taken to the laboratory and will be kept as a non-irradiated control.
Study: NCT04774250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide 100Mg Cap
Description: ZONEGRAN® is commercially available for oral administration as capsules containing 100 mg of Zonisamide.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will contain microcrystalline cellulose which is the predominant filler in the generic capsule.
Study: NCT04782791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab plus SOX
Description: The preoperative therapy consists of three-week cycles of intravenously administered nivolumab 360mg and oxaliplatin 130mg/m2 on day 1, and orally administered S-1 40-60 mg twice a day (BID) on day 1 to 14. The dose of S-1 depends on body surface area (BSA): BSA\<1.25 m2, 40mg; 1.25\<BSA\<1.50 m2, 50mg; BSA\>1.50 m2, 60mg. Day 15 to day 21 is the rest period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: The preoperative therapy consists of three-week cycles of intravenously administered nivolumab 360mg on day 1.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastrectomy
Description: A standard D2 radical laparoscopic gastrectomy according to the CSCO clinical guidelines for the diagnosis and treatment of gastric cancer is planned 3-4 weeks after the last cycle of preoperative therapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastrectomy
Description: A standard D2 radical laparoscopic gastrectomy according to the CSCO clinical guidelines for the diagnosis and treatment of gastric cancer is planned 3-4 weeks after the last cycle of preoperative therapy.
Study: NCT06387017

Intervention type: RADIATION
Group type: OTHER
Intervention: low dose CT scan
Description: low dose CT scan evaluation
Study: NCT06216093

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EuRSV
Description: Healthy adults received 0.5mL single intramuscular dose on Day 0 and Day 28.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EuRSV
Description: Healthy adults received 0.5mL single intramuscular dose on Day 0 and Day 28.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Healthy adults received 0.5mL single intramuscular dose on Day 0 and Day 28.
Study: NCT04514783

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Debridement with Debritom+ micro water jet device
Description: Visits to the outpatient wound-care center as directed by a physician. Wound care performed by the study nurse according to the study-protocol. Each necessary wound debridement will be the same and will be as follows:~* Removal of old dressing~* Woundworks® 3D imaging~* Applying analgesic if necessary~* Applying a soaked gaze with Sodium chloride (NaCl) 0.9% solution on the wound (5 minutes)~* Debridement using Debritom+ micro water jet technology~* Wound cleansing with NaCl 0.9% solution~* Woundworks® 3D imaging~* Application of new dressing (according to the wound healing phases, medical prescription)~In the case debridement is no more required, wound dressing change will be performed as follows:~* Removal of old dressing~* Woundworks® 3D imaging~* Wound cleansing with NaCl 0.9% solution~* Application of new dressing (according to the wound healing phases, medical prescription)

Intervention type: OTHER
Group type: OTHER
Intervention: Debridement with
Description: Visits to the outpatient wound-care center as directed by a physician. Wound care performed by the respective study nurse according to the study-protocol. Each necessary wound debridement will be the same and will be as follows:~* Removal of old dressing~* Woundworks® 3D imaging~* Applying analgesic if necessary~* Applying a soaked gaze with NaCl 0.9% solution on the wound (5 minutes)~* Debridement using scalpel and curette~* Wound cleansing with NaCl 0.9% solution~* Woundworks® 3D imaging~* Application of new dressing (according to the wound healing phases, medical prescription)~In the case debridement is no more required, wound dressing change will be performed as follows:~* Removal of old dressing~* Woundworks® 3D imaging~* Wound cleansing with NaCl 0.9% solution~* Application of new dressing (according to the wound healing phases, medical prescription)
Study: NCT05820737

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EF2001
Description: One capsule to be consumed once a day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: beLP1
Description: One capsule to be consumed once a day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule to be consumed once a day
Study: NCT06007079

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPM Device
Description: Wearable monitor
Study: NCT06306560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adebrelimab
Description: adebrelimab IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: famitinib
Description: famitinib PO
Study: NCT04897139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flu-Bu-Mel-E
Description: Fludarabine 150mg/m2, busulfan 6.4mg/kg, melphalan 100mg/m2 and etoposide 600mg/m2
Study: NCT06129357

Intervention type: BEHAVIORAL
Intervention: 180 individuals who applied to the Periodontology Clinic were included in the study. Individuals were divided into 3 groups as healthy (n=60), gingivitis (n=60) and periodontitis (n=60).
Description: Diagnostic Test: Full periodontal chart A full periodontal chart will be carried out including all biometric periodontal variables: Probing Pocket Depth (PPD), Bleeding on Probing (BoP), presence of Plaque, recession (REC), Full Mouth Plaque Score (FMPS), Full Mouth Bleeding Score (FMBS), presence of furcation and mobility. Periodontal status, as assessed by the periodontal chart, will be evaluated following the New Classification of Periodontal and Peri implant diseases.

Intervention type: BEHAVIORAL
Intervention: 180 individuals who applied to the Periodontology Clinic were included in the study. Individuals were divided into 3 groups as healthy (n=60), gingivitis (n=60) and periodontitis (n=60).
Description: Diagnostic Test: Full periodontal chart A full periodontal chart will be carried out including all biometric periodontal variables: Probing Pocket Depth (PPD), Bleeding on Probing (BoP), presence of Plaque, recession (REC), Full Mouth Plaque Score (FMPS), Full Mouth Bleeding Score (FMBS), presence of furcation and mobility. Periodontal status, as assessed by the periodontal chart, will be evaluated following the New Classification of Periodontal and Peri implant diseases.

Intervention type: BEHAVIORAL
Intervention: 180 individuals who applied to the Periodontology Clinic were included in the study. Individuals were divided into 3 groups as healthy (n=60), gingivitis (n=60) and periodontitis (n=60).
Description: Diagnostic Test: Full periodontal chart A full periodontal chart will be carried out including all biometric periodontal variables: Probing Pocket Depth (PPD), Bleeding on Probing (BoP), presence of Plaque, recession (REC), Full Mouth Plaque Score (FMPS), Full Mouth Bleeding Score (FMBS), presence of furcation and mobility. Periodontal status, as assessed by the periodontal chart, will be evaluated following the New Classification of Periodontal and Peri implant diseases.
Study: NCT05470257

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cast
Description: Application of fiberglass long arm cast.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cast
Description: Application of fiberglass long arm cast.
Study: NCT06518850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Both groups were treated with rifaximin for 14 days, during which follow-up records were reported by the subjects in the daily reference case report form. Methane and hydrogen breath tests were repeated 2 weeks after withdrawal.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Rifaximin
Description: Both groups were treated with rifaximin for 14 days, during which follow-up records were reported by the subjects in the daily reference case report form. Methane and hydrogen breath tests were repeated 2 weeks after withdrawal.
Study: NCT06371183

Intervention type: DEVICE
Group type: OTHER
Intervention: Colonoscope
Description: Endoscopy for lower GIT
Study: NCT05232370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme inhibitor
Description: Angiotensin-converting enzyme inhibitors after Kidney Transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin Receptor Blockers
Description: Angiotensin receptor blockers after Kidney Transplant
Study: NCT05324865

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation
Description: Progressive Muscle Relaxation PMR is a technique that provides relaxation in the whole body by voluntary and regular relaxation of large muscle groups in the human body, which is included in mind-body applications.
Study: NCT06306560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: chemotherapy IV
Study: NCT06080230

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Participants in the 8-week program
Description: Psychological resilience program based on positive psychotherapy was applied to nurses
Study: NCT05011279

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Move Together app/Garmin Activity Tracker
Description: * The Move Together app allows users to set daily goals for increasing physical activity and decreasing sedentary time, track progress on goals, message their buddy, and access external educational infographics and other resource links.~* Garmin activity tracker in this study is for participants to track their steps and sedentary time.
Study: NCT05027295

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: riboflavin ophthalmic solution
Description: Administration of riboflavin one drop every 2 minutes during administration of continuous UVA light for 7.5 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: riboflavin ophthalmic solution
Description: Administration of riboflavin one drop every 2 minutes during administration of pulsed UVA light for 15 minutes
Study: NCT05869357

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cream containing 2.5% sericin and 2%turmeric
Description: Sample is applied 2 times/day for 6 days. Then, use of the sample is stopped for 7 to 10 days. After that, sample is applied 2 times/day for 3days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cream containing 5%sericin and 2%turmeric
Description: Sample is applied 2 times/day for 6 days. Then, use of the sample is stopped for 7 to 10 days. After that, sample is applied 2 times/day for 3days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cream containing 10%sericin and 2%turmeric
Description: Sample is applied 2 times/day for 6 days. Then, use of the sample is stopped for 7 to 10 days. After that, sample is applied 2 times/day for 3days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cream base
Description: Sample is applied 2 times/day for 6 days. Then, use of the sample is stopped for 7 to 10 days. After that, sample is applied 2 times/day for 3days.
Study: NCT05765773

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CoviVac vaccine (inactivated whole-virion concentrated purified) manufactured by FSBSI Chumakov FSC R&D IBP RAS
Description: 200 volunteers who will be vaccinated with the CoviVac vaccine three times with an interval of 21 days intramuscularly at a dose of 0.5 ml.
Study: NCT05061680

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic short duration papillary large balloon dilation
Description: During the large balloon papillary dilation investigators follow the cholangiogram and stop the dilatation as soon as the disappearance of the waist of the papilla is noticed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic short duration papillary large balloon dilation
Description: During the large balloon papillary dilation investigators follow the cholangiogram and stop the dilatation as soon as the disappearance of the waist of the papilla is noticed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic short duration papillary large balloon dilation
Description: During the large balloon papillary dilation investigators follow the cholangiogram and stop the dilatation as soon as the disappearance of the waist of the papilla is noticed.
Study: NCT05292898

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LCAR-AIO Cells
Description: LCAR-AIO Cells before treatment with LCAR-AIO cells, subjects will receive a conditioning regimen (IV infusion of cyclophosphamide 300 mg/m\^2 and fludarabine 30mg/m\^2 once daily (QD) for 3 days.
Study: NCT05778383

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc Acetate
Description: Each participant allocated in the intervention arm will be treated as Standard of Care and will be supplemented with 240mg of Zinc Acetate
Study: NCT05046444

Intervention type: DIAGNOSTIC_TEST
Intervention: Next Generation Sequencing
Description: NON-Interventional Observation only study comparing sequencing-only approaches to classical diagnostic methods
Study: NCT05172479

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of qSOFA score
Description: At the patient's arrival to the ED triage, the nurse will enter the patient's vital signs data into electronic data capture (EDC) system that will calculate the patient's qSOFA score.

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of qSOFA score
Description: At the patient's arrival to the ED triage, the nurse will enter the patient's vital signs data into electronic data capture (EDC) system that will calculate the patient's qSOFA score.

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of SIRS criteria
Description: At the patient's arrival to the ED triage, the nurse will enter the patient's vital signs data into electronic data capture (EDC) system that will calculate the patient's SIRS criteria.

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of SIRS criteria
Description: At the patient's arrival to the ED triage, the nurse will enter the patient's vital signs data into electronic data capture (EDC) system that will calculate the patient's SIRS criteria.

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of NEWS
Description: At the patient's arrival to the ED triage, the nurse will enter the patient's vital signs data into electronic data capture (EDC) system that will calculate the patient's NEWS.

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of NEWS
Description: At the patient's arrival to the ED triage, the nurse will enter the patient's vital signs data into electronic data capture (EDC) system that will calculate the patient's NEWS.

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of NEWS2
Description: At the patient's arrival to the ED triage, the nurse will enter the patient's vital signs data into electronic data capture (EDC) system that will calculate the patient's NEWS2.

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of NEWS2
Description: At the patient's arrival to the ED triage, the nurse will enter the patient's vital signs data into electronic data capture (EDC) system that will calculate the patient's NEWS2.

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of MEWS
Description: At the patient's arrival to the ED triage, the nurse will enter the patient's vital signs data into electronic data capture (EDC) system that will calculate the patient's MEWS.

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of MEWS
Description: At the patient's arrival to the ED triage, the nurse will enter the patient's vital signs data into electronic data capture (EDC) system that will calculate the patient's MEWS.
Study: NCT06107179

Intervention type: DIAGNOSTIC_TEST
Intervention: Multispectral Optoacoustic Tomography
Description: In MSOT, laser light is emitted into the target tissue via a handheld probe. Thermoelastic expansion of various molecules in the target area generates ultrasound waves that are detected by the transducer. The detected signals are reconstructed into images using algorithms. Spectral analysis of the optoacoustic signal at different wavelengths in the near-infrared range can detect individual chromophores, such as oxygenated and deoxygenated hemoglobin.

Intervention type: DIAGNOSTIC_TEST
Intervention: Multispectral Optoacoustic Tomography
Description: In MSOT, laser light is emitted into the target tissue via a handheld probe. Thermoelastic expansion of various molecules in the target area generates ultrasound waves that are detected by the transducer. The detected signals are reconstructed into images using algorithms. Spectral analysis of the optoacoustic signal at different wavelengths in the near-infrared range can detect individual chromophores, such as oxygenated and deoxygenated hemoglobin.
Study: NCT05130671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Standard of care treatment as per the hospital guidelines

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care treatment as per the hospital guidelines

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Investigational treatment
Description: Combination of quercetin and curcumin as add-on to the standard of care
Study: NCT06246383

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Q Actin
Description: cucumber extract

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Q Actin
Description: cucumber extract
Study: NCT01006343

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Higher Protein (HP)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower Protein (LP)